Search results: (10000)
News ADCT – a simple tool for self-diagnosis of patients with severe atopic dermatitis
Atopic dermatitis (AD) is a chronic inflammatory disease not only of childhood. It can negatively affect the quality of life despite being treatable. Control and management of the disease in different areas of life can be easily evaluated using the ADCT questionnaire.
News Fixed Combination of Trastuzumab and Pertuzumab for Subcutaneous Administration in Patients with Early Breast Cancer
At a symposium focused on breast cancer, held in December 2019 in San Antonio, Texas, preliminary results of the FeDeriCa clinical study were presented – comparing the pharmacokinetics, efficacy, and safety of a fixed combination of trastuzumab and pertuzumab for subcutaneous administration versus intravenous administration in patients with early-stage HER2-positive breast cancer. Based on the presented results, the drug received approval from the U.S. Food and Drug Administration (FDA).
News Results of Prophylactic Treatment of Severe von Willebrand Disease with Recombinant vWF
The phase III study cited below evaluated the efficacy and safety of 12-month prophylaxis with recombinant von Willebrand factor (rvWF) in 23 patients with severe von Willebrand disease (vWD), who had previously been treated either on-demand (during spontaneous bleeding episodes) or had been on prophylaxis with plasma-derived vWF (pdvWF).
News Influence of ARNI on the Efficacy and Safety of Empagliflozin in the Treatment of Heart Failure with Reduced Ejection Fraction
Pharmacological inhibition of neprilysin and the AT1 receptor for angiotensin II (ARNI) through sacubitril/valsartan reduces cardiovascular (CV) mortality and the risk of hospitalization for heart failure. The same benefit has also been demonstrated with the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i), also known as gliflozins. A pre-specified sub-analysis of the EMPEROR-Reduced study evaluated whether the benefit of SGLT2i is also significant in patients treated with ARNI.
News Post-COVID-19 Patient Care from the Perspective of Experts Across Fields
For many patients with COVID-19, overcoming the acute phase is crucial, but we now know that the disease may not end there. Some patients even manage the acute stage with very mild symptoms, and significant difficulties arise later in the form of 'post-COVID syndrome.' This issue was discussed in detail at a January webinar by leading experts from various fields.
News Summary Analysis of HAVEN 1–4 and Patient Case Studies from ÚHKT
MUDr. Věra Geierová from the Institute of Hematology and Blood Transfusion in Prague prepared a summary of what was discussed about emicizumab during the ASH 2020 congress for this year's Prague Hematology Days. In this context, she highlighted the comprehensive analysis of phase 3 HAVEN 1–4 studies, which assessed the safety and efficacy of emicizumab in individuals with hemophilia A with or without FVIII inhibitors.
News Stabilization of Transthyretin and Long-term Survival of Patients with Cardiac Amyloidosis
Tafamidis is used in the therapy of transthyretin amyloid cardiomyopathy (ATTR-CM), which has proven its benefit in the ATTR-ACT clinical study. The results of its open-label extension study show that early diagnosis and prompt initiation of therapy are crucial.
News Benefits of Physical Activity for Individuals with Hemophilia – Recommendations of the MEMO Group
Regular physical activity can increase joint stability and function in individuals with hemophilia, reduce the risk of injury, improve quality of life, and have other positive effects. However, according to recent findings, a regular exercise program is not sufficiently emphasized in comprehensive hemophilia therapy. Therefore, a group of Italian experts has created a consensus summarizing current knowledge about the benefits of exercise for individuals with hemophilia and recommendations for physical activity.
News Do ACE Inhibitors Have a Protective Effect in People with COVID-19?
Although the COVID-19 pandemic has not lasted even a year, a number of studies have already been processed, examining the influence of various factors on the morbidity and mortality of patients. The presented meta-analysis investigated the influence of ACE inhibitors on the mortality of patients with this disease.
News Should patients with primary immunodeficiencies fear COVID-19 more than the general population?
The body fights the new SARS-CoV-2 virus, which causes COVID-19, in a similar way to other viral infections - by intensely engaging the immune system. But what if it's weakened?
News Prediabetes as a Risk Factor for Overall Mortality and Development of CVD
Prediabetes represents a glucose metabolism disorder with a high risk of developing diabetes. According to the expert panel of the American Diabetes Association (ADA), this risk is up to 70%. A recently published meta-analysis confirms that prediabetes is a significant risk factor for mortality and the development of cardiovascular (CV) diseases not only in the general population but also in patients with known CV disease, and its treatment should therefore be part of cardiovascular prevention.
News Overview of the Efficacy of the Fixed Combination Aclidinium-Bromide/Formoterol-Fumarate in the Maintenance Treatment of COPD
Fixed combination inhalation medications have become the cornerstone of pharmacotherapy for moderate to severe chronic obstructive pulmonary disease (COPD). American authors have published an overview of study results evaluating the efficacy and safety of one of the newest fixed combinations of LABA/LAMA, aclidinium-bromide and formoterol-fumarate (AB/FF), in the maintenance treatment of COPD compared to placebo or other medications. These clinical studies investigated the extent to which regular use of this fixed combination alleviates COPD symptoms, improves lung function, reduces the incidence of exacerbations, and increases exercise tolerance.
News Continuation of Treatment with Tofacitinib in Rheumatoid Arthritis – Real-World Clinical Practice Data
The oral Janus kinase inhibitor tofacitinib has been extensively tested in patients with rheumatoid arthritis in numerous international randomized clinical trials. According to a recently published review summarizing retrospective, prospective, and observational studies from real-world clinical practice published in 2018–2020, the treatment duration with tofacitinib is comparable to that with biological disease-modifying drugs.
News Long-term Clinical and Radiological Results of Implantation of Cementless Corail Stem
The Corail femoral stem with extensive hydroxyapatite coating for cementless implantation was introduced to the market several decades ago. The study cited below evaluated the clinical and radiological results of the implantation of this type of stem over a 20-year horizon in patients who underwent primary total hip arthroplasty.
News Antiviral and Anti-inflammatory Effects of Alpha-1-Antitrypsin in the Treatment of COVID-19
Human alpha-1-antitrypsin (AAT) is a circulating blood glycoprotein that has been used for decades in the treatment of patients with AAT deficiency, lung damage, and emphysema, helping to prevent acute lung injury. Recently, it has been found that AAT also mitigates the course of COVID-19 disease by hindering the entry of the SARS-CoV-2 coronavirus into host cells. This dual antiviral and anti-inflammatory action makes AAT an excellent candidate for COVID-19 treatment.
News Summary of Guidelines for the Diagnosis, Prevention, and Treatment of Invasive Fungal Infections in Pediatric Patients with Leukemia and Post Hematopoietic Stem Cell Transplantation
Invasive fungal diseases are a significant cause of morbidity and mortality among immunocompromised pediatric patients with leukemia and post-hematopoietic stem cell transplantation. During the 8th European Conference on Infections in Leukemia (ECIL-8) in 2020, the pediatric group reviewed and updated recommendations for the diagnosis, prevention, and treatment of invasive fungal infections in pediatric patients.
News Effect of Trifluridine/Tipiracil Combination Depending on Patient Prognosis
The results of the RECOURSE clinical study were published in 2015 and became an important basis for the approval of the trifluridine/tipiracil combination in the treatment of metastatic colorectal cancer (mCRC). The data obtained in this study were also subjected to several post-hoc analyses. One of these recently brought information on how patient prognosis affects the clinical outcomes of this treatment.
News Clinical Significance of Smaller Gaps Between Strengths of Levothyroxine Preparations in the Treatment of Hypothyroidism
Many levothyroxine preparations have relatively large intervals between doses (25 µg, 50 µg, and 75 µg), creating obstacles for some patients to achieve an optimal maintenance dose. The availability of tablets that allow for dosing in between these values facilitates precise and effective titration of levothyroxine doses, especially at the lower end of the spectrum.
News Less Ventricular Arrhythmias and ICD Shocks After Introduction of Sacubitril/Valsartan
Is the decrease in the incidence of sudden cardiac death among patients using sacubitril/valsartan due to a lower risk of ventricular arrhythmias? And does it have anything to do with reverse left ventricular remodeling? A newly published study utilizing data from telemonitoring of patients with implanted devices focused on this.
News How to Secure Diabetics with Atrial Fibrillation During PCI?
Optimal management of patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI) continues to be the subject of studies. A sub-analysis of the RE-DUAL study focused on this issue in a high-risk group of patients with diabetes.
News Is the combination of tiotropium/olodaterol proven more effective in reducing the risk of clinically significant worsening of COPD compared to monotherapy?
Given the heterogeneity of chronic obstructive pulmonary disease (COPD), the use of a composite parameter that includes lung function, the occurrence of exacerbations, and quality of life offers a more comprehensive view of treatment outcomes. Such a parameter was used in the analysis of the TONADO studies, which compared early use of the fixed combination of tiotropium/olodaterol with tiotropium alone.
News How Common is Alpha-1 Antitrypsin Deficiency?
What is the prevalence of alpha-1 antitrypsin deficiency (AATD)? What comorbidities are associated with it? Are healthcare costs for these patients higher compared to patients with unrelated obstructive lung diseases? Awareness of AATD is low and prevalence data are only indicative. The authors of a study published in the European Respiratory Journal aimed to map this disease in a population of 4 million German insured individuals.
News Impact of Alpha-1 Antitrypsin Deficiency on Quality of Life and Mental Health of Patients
The clinical manifestation of alpha-1 antitrypsin deficiency and its impact on quality of life are highly heterogeneous. This contribution by pulmonologist Robert Sandhaus summarizes interesting findings from studies on the quality of life of patients with this disease and the factors influencing it.
News Deep stimulation of the globus pallidus improved clinical symptoms in a patient with refractory parkinsonism and genetic mutation
The authors of the presented work studied the effects of deep brain stimulation (DBS) in a patient with Parkinson's disease with a genetic mutation that manifests in early adulthood.